Cheryl R. Blanchard

2021 - Anika Therapeutics

In 2021, Cheryl R. Blanchard earned a total compensation of $4.2M as President and Chief Executive Officer at Anika Therapeutics, a 58% decrease compared to previous year.

Compensation breakdown

Bonus$568,140
Option Awards$1,471,831
Salary$668,400
Stock Awards$1,470,806
Other$23,431
Total$4,202,608

Blanchard received $1.5M in option awards, accounting for 35% of the total pay in 2021.

Blanchard also received $568.1K in bonus, $668.4K in salary, $1.5M in stock awards and $23.4K in other compensation.

Rankings

In 2021, Cheryl R. Blanchard's compensation ranked 3,179th out of 12,415 executives tracked by ExecPay. In other words, Blanchard earned more than 74.4% of executives.

ClassificationRankingPercentile
All
3,179
out of 12,415
74th
Division
Manufacturing
1,286
out of 5,505
77th
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
153
out of 801
81st
Industry group
Surgical, Medical, And Dental Instruments And Supplies
99
out of 522
81st
Industry
Surgical and Medical Instruments and Apparatus
67
out of 327
80th
Source: SEC filing on April 27, 2022.

Blanchard's colleagues

We found four more compensation records of executives who worked with Cheryl R. Blanchard at Anika Therapeutics in 2021.

2021

Michael Levitz

Anika Therapeutics

Chief Financial Officer

2021

David Colleran

Anika Therapeutics

General Counsel

2021

Thomas Finnerty

Anika Therapeutics

EVP, Human Resources

2021

James Loerop

Anika Therapeutics

EVP, Business Development and Strategic Planning

News

You may also like